Recent advances in “smart” delivery systems for extended drug release in cancer therapy

References

• TorchilinVPMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryNat Rev Drug Discov2014131181382725287120
   PubMed Web of Science ®Google Scholar
• FornagueraCGarcía-CelmaMPersonalized nanomedicine: a revolution at the nanoscaleJ Pers Med201774E1229023366
   PubMed Web of Science ®Google Scholar
• HareJILammersTAshfordMBPuriSStormGBarrySTChallenges and strategies in anti-cancer nanomedicine development: an industry perspectiveAdv Drug Deliv Rev2017108253827137110
   PubMed Web of Science ®Google Scholar
• LammersTImproving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulationsAdv Drug Deliv Rev201062220323019951732
   PubMed Web of Science ®Google Scholar
• YangMYuLGuoRDongALinCZhangJA modular coassembly approach to all-in-one multifunctional nanoplatform for synergistic codelivery of doxorubicin and curcuminNanomaterials201883E16729543780
   PubMed Web of Science ®Google Scholar
• LiXSzewczukMMalardier-JugrootCFolic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platformDrug Des Devel Ther20161041014110
   PubMed Web of Science ®Google Scholar
• GuFXKarnikRWangAZTargeted nanoparticles for cancer therapyNano Today2007231421
   Web of Science ®Google Scholar
• RodzinskiAGuduruRLiangPTargeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticlesSci Rep201662086726875783
   PubMed Web of Science ®Google Scholar
• Pérez-HerreroEFernández-MedardeAAdvanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapyEur J Pharm Biopharm201593527925813885
   PubMed Web of Science ®Google Scholar
• BlancoEShenHFerrariMPrinciples of nanoparticle design for overcoming biological barriers to drug deliveryNat Biotechnol201533994195126348965
   PubMed Web of Science ®Google Scholar
• HoneyPJRijoJAnjuAAnoopKRSmart polymers for the controlled delivery of drugs: a concise overviewActa Pharm Sin B20144212012726579373
   PubMed Web of Science ®Google Scholar
• MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
   PubMed Web of Science ®Google Scholar
• DanhierFFeronOPréatVTo exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJ Control Release2010148213514620797419
   PubMed Web of Science ®Google Scholar
• BaeYHDrug targeting and tumor heterogeneityJ Control Release200913312318848589
   PubMed Web of Science ®Google Scholar
• BaeYHParkKTargeted drug delivery to tumors: myths, reality and possibilityJ Control Release2011153319820521663778
   PubMed Web of Science ®Google Scholar
• HeldinCHRubinKPietrasKÖstmanAHigh interstitial fluid pressure: an obstacle in cancer therapyNat Rev Cancer200441080681315510161
   PubMed Web of Science ®Google Scholar
• JainRKStylianopoulosTDelivering nanomedicine to solid tumorsNat Rev Clin Oncol201071165366420838415
   PubMed Web of Science ®Google Scholar
• LiXMctaggartMMalardier-JugrootCSynthesis and characterization of a pH responsive folic acid functionalized polymeric drug delivery systemBiophys Chem2016214–2151726
   PubMed Web of Science ®Google Scholar
• WangMThanouMTargeting nanoparticles to cancerPharmacol Res2010622909920380880
   PubMed Web of Science ®Google Scholar
• BoboDRobinsonKJIslamJThurechtKJCorrieSRNanoparticle-based medicines: a review of FDA-approved materials and clinical trials to datePharm Res201633102373238727299311
   PubMed Web of Science ®Google Scholar
• LammersTRizzoLYStormGKiesslingFPersonalized nanomedi-cineClin Cancer Res201218184889489422829203
   PubMed Web of Science ®Google Scholar
• ByrneJDBetancourtTBrannon-PeppasLActive targeting schemes for nanoparticle systems in cancer therapeuticsAdv Drug Deliv Rev200860151615162618840489
   PubMed Web of Science ®Google Scholar
• RenouxBRaesFLegiganTTargeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancersChem Sci2017853427343328507714
   PubMed Web of Science ®Google Scholar
• WangZZhengQZhangHOntak-like human IL-2 fusion toxinJ Immunol Methods2017448515828551309
   PubMed Web of Science ®Google Scholar
• ChenWCZhangAXLiSDLimitations and niches of the active targeting approach for nanoparticle drug deliveryEur J Nanomed201242–48993
   Google Scholar
• QuCXLiJZZhouYJTargeted delivery of doxorubicin via CD147-mediated ROS/pH dual-sensitive nanomicelles for the efficient therapy of hepatocellular carcinomaAAPS J20182023429476273
   PubMed Web of Science ®Google Scholar
• AdochiteRCMoshnikovaACarlinSDTargeting breast tumors with pH (low) insertion peptidesMol Pharm20141182896290525004202
   PubMedGoogle Scholar
• AdochiteRCMoshnikovaAGolijaninJAndreevOAKatenkaNVReshetnyakYKComparative study of tumor targeting and biodistribution of pH (low) insertion peptides (pHLIP peptides) conjugated with different fluorescent dyesMol Imaging Biol201618568669627074841
   PubMed Web of Science ®Google Scholar
• WeerakkodyDMoshnikovaAel-SayedNSNovel pH-sensitive cyclic peptidesSci Rep201663132227515582
   PubMed Web of Science ®Google Scholar
• VogelSMMinshallRDPilipovićMTiruppathiCMalikABAlbumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding proteinAm J Physiol Lung Cell Mol Physiol20012816L1512L152211704548
   PubMed Web of Science ®Google Scholar
• FreiEAlbumin binding ligands and albumin conjugate uptake by cancer cellsDiabetol Metab Syndr2011311121676260
   PubMedGoogle Scholar
• DesaiNPTrieuVHwangLYWuRSoon-ShiongPGradisharWJImproved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnticancer Drugs200819989990918766004
   PubMed Web of Science ®Google Scholar
• ChoiKYSaravanakumarGParkJHParkKHyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancerColloids Surf B Biointerfaces201299829422079699
   PubMed Web of Science ®Google Scholar
• TaheriADinarvandRAtyabiFNouriFTargeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticlesJ Biomed Nanotechnol20117674375322416572
   PubMed Web of Science ®Google Scholar
• TaheriADinarvandRNouriFSUse of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance metho-trexate antitumor efficacyInt J Nanomedicine201161863187421931482
   PubMed Web of Science ®Google Scholar
• PatilYBTotiUSKhdairAMaLPanyamJSingle-step surface functionalization of polymeric nanoparticles for targeted drug deliveryBiomaterials200930585986619019427
   PubMed Web of Science ®Google Scholar
• ParveenSSahooSKEvaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastomaCancer Nanotechnol201011–6476226069479
   PubMedGoogle Scholar
• HrkachJvon HoffDAliMMPreclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profileSci Transl Med20124128128ra139
   Google Scholar
• von HoffDDMitaMMRamanathanRKPhase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumorsClin Cancer Res201622133157316326847057
   PubMed Web of Science ®Google Scholar
• HongMZhuSJiangYNovel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticlesJ Control Release20101411222919735683
   PubMed Web of Science ®Google Scholar
• VisserCCStevanovićSVoorwindenLHValidation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitroJ Drug Target200412314515015203893
   PubMed Web of Science ®Google Scholar
• GanCWFengSSTransferrin-conjugated nanoparticles of poly(lactide)-d-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrierBiomaterials201031307748775720673685
   PubMed Web of Science ®Google Scholar
• JainAChasooGSinghSKSaxenaAKJainSKTransferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisationJ Microencapsul2011281212821171813
   PubMed Web of Science ®Google Scholar
• CampERWangCLittleECTransferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapyCancer Gene Ther201320422222823470564
   PubMed Web of Science ®Google Scholar
• LiuJWeiTZhaoJMultifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistanceBiomaterials201691445626994877
   PubMed Web of Science ®Google Scholar
• SilvaCOPetersenSBReisCPEGF functionalized polymer-coated gold nanoparticles promote EGF photostability and EGFR internalization for photothermal therapyPLoS One20161110e016541927788212
   PubMed Web of Science ®Google Scholar
• Cirstoiu-HapcaABucheggerFBossyLKosinskiMGurnyRDelieFNanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cellsEur J Pharm Sci200938323023719632322
   PubMed Web of Science ®Google Scholar
• WangZChuiWKHoPCHoPCDesign of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cellsPharm Res20092651162117119191012
   PubMed Web of Science ®Google Scholar
• DanhierFVromanBLecouturierNTargeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxelJ Control Release2009140216617319699245
   PubMed Web of Science ®Google Scholar
• MaoBLiuCZhengWCyclic cRGDfk peptide and chlorin e6 functionalized silk fibroin nanoparticles for targeted drug delivery and photodynamic therapyBiomaterials201816130632029427926
   PubMed Web of Science ®Google Scholar
• XinHJiangXGuJAngiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain gliomaBiomaterials2011324293430521427009
   PubMed Web of Science ®Google Scholar
• Yusuf-MakagiansarHSiahaanTJBinding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cellsPharm Res200118332933511442273
   PubMed Web of Science ®Google Scholar
• ChittasuphoCXieSXBaoumAYakovlevaTSiahaanTJBerklandCJICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cellsEur J Pharm Sci200937214115019429421
   PubMed Web of Science ®Google Scholar
• ObaidGChambrierICookMJRussellDACancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticlesPhotochem Photobiol Sci201514473774725604735
   PubMed Web of Science ®Google Scholar
• BhatRGarcíaIAznarELectin-gated and glycan functionalized mesoporous silica nanocontainers for targeting cancer cells overexpressing Lewis X antigenNanoscale2018101239249
   Web of Science ®Google Scholar
• WuXTanYJTohHTStimuli-responsive multifunctional glyconanoparticle platforms for targeted drug delivery and cancer cell imagingChem Sci2017853980398828553540
   PubMed Web of Science ®Google Scholar
• FrickSUDomogallaMPBaierGInterleukin-2 functionalized nanocapsules for T cell-based immunotherapyACS Nano20161092169226
   PubMed Web of Science ®Google Scholar
• SinghRLillardJWNanoparticle-based targeted drug deliveryExp Mol Pathol200986321522319186176
   PubMed Web of Science ®Google Scholar
• LeeESNaKBaeYHDoxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJ Control Release2005103240541815763623
   PubMed Web of Science ®Google Scholar
• SuzukiRTakizawaTKuwataYEffective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposomeInt J Pharm20083461–214315017640835
   PubMed Web of Science ®Google Scholar
• SahooSKMaWLabhasetwarVEfficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancerInt J Cancer2004112233534015352049
   PubMed Web of Science ®Google Scholar
• BartlettDWSuHHildebrandtIJWeberWADavisMEImpact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingProc Natl Acad Sci U S A200710439155491555417875985
   PubMed Web of Science ®Google Scholar
• GradisharWJAlbumin-bound paclitaxel: a next-generation taxaneExpert Opin Pharmacother2006781041105316722814
   PubMed Web of Science ®Google Scholar
• PieterszGAWangXYapMLLimBPeterKTherapeutic targeting in nanomedicine: the future lies in recombinant antibodiesNanomedicine (Lond)201712151873188928703636
   PubMed Web of Science ®Google Scholar
• ChengZal ZakiAHuiJZMuzykantovVRTsourkasAMultifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilitiesScience2012338610990391023161990
   PubMed Web of Science ®Google Scholar
• DuJLaneLANieSStimuli-responsive nanoparticles for targeting the tumor microenvironmentJ Control Release201521920521426341694
   PubMed Web of Science ®Google Scholar
• ZhaoXLiuPReduction-responsive core–shell–corona micelles based on triblock copolymers: novel synthetic strategy, characterization, and application as a tumor microenvironment-responsive drug delivery systemACS Appl Mater Interfaces20157116617425394962
   PubMed Web of Science ®Google Scholar
• AdiseshaiahPPCristRMHookSSMcneilSENanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancerNat Rev Clin Oncol2016131275076527531700
   PubMed Web of Science ®Google Scholar
• NielsenMFMortensenMBDetlefsenSKey players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cellsWorld J Gastroenterol20162292678270026973408
   PubMed Web of Science ®Google Scholar
• Bhaw-LuximonAJhurryDNew avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: selective stroma depletion combined with nano drug deliveryCancer Lett2015369226627326415628
   PubMed Web of Science ®Google Scholar
• KennedyEJBiological drug products: development and strategiesChemMedChem201491228142815
   Google Scholar
• KalimuthuKLubinBCBazylevichAGold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cellsJ Nanobiotechnology20181613429602308
   PubMed Web of Science ®Google Scholar
• TranSDegiovanniPJPielBRaiPCancer nanomedicine: a review of recent success in drug deliveryClin Transl Med201764429230567
   PubMed Web of Science ®Google Scholar
• RahmanAMYusufSWEwerMSAnthracycline-induced cardio-toxicity and the cardiac-sparing effect of liposomal formulationInt J Nanomedicine20072456758318203425
   PubMed Web of Science ®Google Scholar
• BatistGCardiac safety of liposomal anthracyclinesCardiovasc Toxicol200772727417652807
   PubMed Web of Science ®Google Scholar
• KundrandaMNiuJAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsDrug Des Devel Ther2015937673777
   PubMedGoogle Scholar
• UntchMJackischCSchneeweissANab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto – GBG 69): a randomised, phase 3 trialLancet Oncol201617334535626869049
   PubMed Web of Science ®Google Scholar
• ChioreanEGvon HoffDWanYMargunato-DebaySBottemanMGoldsteinDPerformance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancerCancer Manag Res2018101389139629910636
   PubMed Web of Science ®Google Scholar
• HoffmanRMBouvetMNanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancerExpert Opin Pharmacother201516794394725887245
   PubMed Web of Science ®Google Scholar
• MadhavanSGusevYHarrisMG-DOC: a systems medicine platform for personalized oncologyNeoplasia201113977178321969811
   PubMed Web of Science ®Google Scholar
• LeeKChungHImSMulticenter phase II study of a Cremophor-free polymeric micelle-formulated paclitaxel in patients (pts) with metastatic breast cancer (MBC)J Clin Oncol20062418 Suppl10520
   Google Scholar
• NemunaitisJCunninghamCSenzerNPhase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumorsCancer Invest200523867167616377585
   PubMed Web of Science ®Google Scholar
• NorthfeltDWDezubeBJThommesJAEfficacy of PEGylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapyJ Clin Oncol19971526536599053490
   PubMed Web of Science ®Google Scholar
• MaPChenJBiXOvercoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel releaseACS Appl Mater Interfaces20181015123511236329569435
   PubMed Web of Science ®Google Scholar
• ZhouLWangHLiYStimuli-responsive nanomedicines for overcoming cancer multidrug resistanceTheranostics2018841059107429463999
   PubMed Web of Science ®Google Scholar
• LiuJLiJLiuNIn vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cellsInt J Pharm20175301–229129928619457
   PubMed Web of Science ®Google Scholar
• LiJLiuJGuoNZhangXReversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexesInt J Pharm2016511143644527444552
   PubMed Web of Science ®Google Scholar
• GuoNGaoCLiuJReversal of ovarian cancer multidrug resistance by a combination of LAH4-L1-siMDR1 nanocomplexes with chemotherapeuticsMol Pharm20181551853186129621396
   PubMed Web of Science ®Google Scholar
• MisraRDasMSahooBSSahooSKReversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulationInt J Pharm20144751–237238425178825
   PubMedGoogle Scholar
• MasudaYKobayashiHHollandJFOhnumaTReversal of mul-tidrug resistance by a liposome-MDR1 ribozyme complexCancer Chemother Pharmacol19984219169619752
   PubMed Web of Science ®Google Scholar
• GuJFangXHaoJShaXReversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA deliveryBiomaterials2015459911425662500
   PubMed Web of Science ®Google Scholar
• LiJLiangHLiuJWangZPoly(amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapyInt J Pharm20185461–221522529787895
   PubMedGoogle Scholar
• KesharwaniPBanerjeeSGuptaUPAMAM dendrimers as promising nanocarriers for RNAi therapeuticsMater Today20151810565572
   Web of Science ®Google Scholar
• NahaPMukherjeeSByrneHToxicology of engineered nanoparticles: focus on poly(amidoamine) dendrimersInt J Environ Res Public Health2018152E33829443901
   PubMed Web of Science ®Google Scholar
• de JongWHBormPJDrug delivery and nanoparticles: applications and hazardsInt J Nanomedicine20083213314918686775
   PubMed Web of Science ®Google Scholar
• KimYMSongSCTargetable micelleplex hydrogel for long-term, effective, and systemic siRNA deliveryBiomaterials201435277970797724951047
   PubMed Web of Science ®Google Scholar
• KimHJKimAMiyataKKataokaKRecent progress in development of siRNA delivery vehicles for cancer therapyAdv Drug Deliv Rev2016104617727352638
   PubMed Web of Science ®Google Scholar
• SarettSMNelsonCEDuvallCLTechnologies for controlled, local delivery of siRNAJ Control Release20152189411326476177
   PubMed Web of Science ®Google Scholar
• MieleESpinelliGPMieleETomaoFTomaoSAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerInt J Nanomedicine200949910519516888
   PubMed Web of Science ®Google Scholar
• ParkKControlled drug delivery systems: past forward and future backJ Control Release20141903824794901
   PubMed Web of Science ®Google Scholar
• LiuDYangFXiongFGuNThe smart drug delivery system and its clinical potentialTheranostics2016691306132327375781
   PubMed Web of Science ®Google Scholar
• VentolaCLProgress in nanomedicine: approved and investigational nanodrugsPharm Ther20174212742755
   Google Scholar
• MontanaMDucrosCVerhaeghePTermeTVanellePRathelotPAlbumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancersJ Chemother2011232596621571619
   PubMed Web of Science ®Google Scholar
• YanoSZhangYMiwaSSpatial–temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsivenessCell Cycle201413132110211924811200
   PubMed Web of Science ®Google Scholar
• DouerDEfficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic LeukemiaOncologist201621784084727328933
   PubMed Web of Science ®Google Scholar
• SilvermanJADeitcherSRMarqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristineCancer Chemother Pharmacol201371355556423212117
   PubMed Web of Science ®Google Scholar
• DawidczykCMRussellLMSearsonPCNanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developmentsFront Chem201426925202689
   PubMed Web of Science ®Google Scholar
• DavisTFaragSSTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineInt J Nanomedicine201383479348824072970
   PubMed Web of Science ®Google Scholar
• DrummondDCNobleCOGuoZHongKParkJWKirpotinDBDevelopment of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategyCancer Res20066663271327716540680
   PubMed Web of Science ®Google Scholar
• LambYNScottLJLiposomal Irinotecan: a review in metastatic pancreatic adenocarcinomaDrugs201777778579228401446
   PubMed Web of Science ®Google Scholar
• ShahNMohammadASSaralkarPInvestigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastasesPharmacol Res2018132476829604436
   PubMed Web of Science ®Google Scholar
• RafiyathSMRasulMLeeBWeiGLambaGLiuDComparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisExp Hematol Oncol2012111023210520
   PubMedGoogle Scholar
• ForssenEACoulterDMProffittRTSelective in vivo localization of daunorubicin small unilamellar vesicles in solid tumorsCancer Res19925212325532611596882
   PubMed Web of Science ®Google Scholar
• BulbakeUDoppalapudiSKommineniNKhanWLiposomal formulations in clinical use: an updated reviewPharmaceutics201794E1228346375
   PubMed Web of Science ®Google Scholar
• MufamadiMSPillayVChoonaraYEA review on composite liposomal technologies for specialized drug deliveryJ Drug Deliv2011201193985121490759
   PubMedGoogle Scholar
• LancetJEGlUCortesJEFinal results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AMLJ Clin Oncol20163415 Suppl7000
   Web of Science ®Google Scholar
• ChenECFathiATBrunnerAMReformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AMLOnco Targets Ther2018113425343429928134
   PubMed Web of Science ®Google Scholar
• CollierMABachelderEMAinslieKMElectrosprayed myocet-like liposomes: an alternative to traditional liposome productionPharm Res201734241942627896588
   PubMed Web of Science ®Google Scholar
• AgrahariVAgrahariVFacilitating the translation of nanomedicines to a clinical product: challenges and opportunitiesDrug Discov Today201823597499129406263
   PubMed Web of Science ®Google Scholar
• WexJSidhuMOdeyemiIAbou-SettaAMRetsaPTombalBLeuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluationClinicoecon Outcomes Res2013525726923836996
   PubMedGoogle Scholar
• TombalBBergesREligard: advantages for optimal testosterone controlEur Urol Suppl2006518900904
   Web of Science ®Google Scholar
• JainRAThe manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devicesBiomaterials200021232475249011055295
   PubMed Web of Science ®Google Scholar
• DanhierFAnsorenaESilvaJMCocoRle BretonAPréatVPLGA-based nanoparticles: an overview of biomedical applicationsJ Control Release2012161250552222353619
   PubMed Web of Science ®Google Scholar
• PillaiGCeballos-CoronelMLScience and technology of the emerging nanomedicines in cancer therapy: a primer for physicians and pharmacistsSage Open Med201313205031211351375926770691
   PubMedGoogle Scholar
• ZhangFLiuMRWanHTDiscussion about several potential drawbacks of PEGylated therapeutic proteinsBiol Pharm Bull201437333533924334536
   PubMed Web of Science ®Google Scholar
• ShehzadALeeJHuhTLLeeYSCurcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53Mol Cells201335652653223686430
   PubMed Web of Science ®Google Scholar
• KunwarABarikAMishraBRathinasamyKPandeyRPriyadarsiniKIQuantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cellsBiochim Biophys Acta20081780467367918178166
   PubMed Web of Science ®Google Scholar
• CheungABaxHJJosephsDHTargeting folate receptor alpha for cancer treatmentOncotarget2016732525535257427248175
   PubMedGoogle Scholar
• LyonPCGriffithsLFLeeJClinical trial protocol for TAR-DOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox) using focused ultrasound in patients with liver tumoursJ Ther Ultrasound201752829118984
   PubMedGoogle Scholar
• PanyamJZhouWZPrabhaSSahooSKLabhasetwarVRapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene deliveryFASEB J200216101217122612153989
   PubMed Web of Science ®Google Scholar
• RamasamyTTranTHChoiJYLayer-by-layer coated lipid–polymer hybrid nanoparticles designed for use in anticancer drug deliveryCarbohydr Polym201410265366124507332
   PubMed Web of Science ®Google Scholar
• WestesenKBunjesHKochMHPhysicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potentialJ Control Release1997482–3223236
   Web of Science ®Google Scholar
• MolineuxGPEGylation: engineering improved biopharmaceuticals for oncologyPharmacotherapy2003238 Pt 23S8S12921216
   PubMed Web of Science ®Google Scholar
• WangMXieFWenXTherapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cellsNanomedicine (Lond)20171291025104228440698
   PubMed Web of Science ®Google Scholar
• YaoXLYoshiokaYRuanGXOptimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapyBiomacromolecules20121382402240922746837
   PubMed Web of Science ®Google Scholar
• BalalaevaIVZdobnovaTAKrutovaIVBrilkinaAALebedenkoENDeyevSMPassive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenograftsJ Biophotonics2012511–1286086722887708
   PubMed Web of Science ®Google Scholar
• SykesEAChenJZhengGChanWCInvestigating the impact of nanoparticle size on active and passive tumor targeting efficiencyACS Nano2014865696570624821383
   PubMed Web of Science ®Google Scholar
• CortésJRugoHSTwelvesCSafety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trialSpringerplus20165103327441152
   PubMedGoogle Scholar
• ChoKWangXNieSChenZShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res20081451310131618316549
   PubMed Web of Science ®Google Scholar
• LiechtyWBPeppasNAExpert opinion: Responsive polymer nanoparticles in cancer therapyEur J Pharm Biopharm201280224124621888972
   PubMed Web of Science ®Google Scholar
• WangBJiangWYanHNovel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous mediumInt J Nanomedicine201161443145121796246
   PubMed Web of Science ®Google Scholar
• JacksonJKLetchfordKWassermanBZYeLHamadWYBurtHMThe use of nanocrystalline cellulose for the binding and controlled release of drugsInt J Nanomedicine2011632133021383857
   PubMed Web of Science ®Google Scholar
• AmoozgarZWangLBrandstoetterTWallisSSWilsonEMGoldbergMSDual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer modelBiomacromolecules201415114187419425251833
   PubMed Web of Science ®Google Scholar
• ProsperiDColomboMZanoniIGranucciFDrug nanocarriers to treat autoimmunity and chronic inflammatory diseasesSemin Immunol201734616728855088
   PubMed Web of Science ®Google Scholar
• OwenARannardSConsiderations for clinically-relevant nano-medicine therapies for chronic diseasesNanomedicine (Lond)201510203103310726446297
   PubMed Web of Science ®Google Scholar
• HoffmanAPharmacodynamic aspects of sustained release preparationsAdv Drug Deliv Rev199833318519910837659
   PubMed Web of Science ®Google Scholar
• KumariAYadavSKYadavSCBiodegradable polymeric nanoparticles based drug delivery systemsColloids Surf B Biointerfaces201075111819782542
   PubMed Web of Science ®Google Scholar
• SklarJJOHVMLiSCFactors affecting therapeutic compliance: a review from the patient’s perspectiveTher Clin Risk Manag20084126928618728716
   PubMedGoogle Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• VrijensBde GeestSHughesDAA new taxonomy for describing and defining adherence to medicationsBr J Clin Pharmacol201273569170522486599
   PubMed Web of Science ®Google Scholar
• EisenSAMillerDKWoodwardRSSpitznagelEPrzybeckTRThe effect of prescribed daily dose frequency on patient medication complianceArch Intern Med19901509188118842102668
   PubMed Web of Science ®Google Scholar
• NoensLvan LierdeMAde BockRPrevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyBlood2009113225401541119349618
   PubMed Web of Science ®Google Scholar
• WangYSYoungsterSGraceMBauschJBordensRWyssDFStructural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implicationsAdv Drug Deliv Rev200254454757012052714
   PubMed Web of Science ®Google Scholar
• BukowskiRErnstoffMSGoreMEPEGylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II studyJ Clin Oncol200220183841394912228203
   PubMed Web of Science ®Google Scholar
• AtkinsMBHodiFSThompsonJAPembrolizumab (Pembro) plus ipilimumab (Ipi) or PEGylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC)J Clin Oncol20163415 Suppl3013
   Web of Science ®Google Scholar
• NunesATGreenDEkwedeIZoonKAnnunziataCMPhase 1 study of intraperitoneal infusion of autologous monocytes with PEGinter-feron alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancerJ Clin Oncol20163515 Suppl3092
   Google Scholar
• KatsukiSMatobaTKogaJNakanoKEgashiraKAnti-inflammatory nanomedicine for cardiovascular diseaseFront Cardiovasc Med201748729312961
   PubMed Web of Science ®Google Scholar
• BatistGBartonJChaikinPSwensonCWellesLMyocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapyExpert Opin Pharmacother20023121739175112472371
   PubMedGoogle Scholar
• DixitNMauryaSDSagarBPSustained release drug delivery systemIndian J Res Pharm Biotechnol201313305310
   Google Scholar
• TarunPVishalSGauravSSatyanandTChiragPAnilGNovel oral sustained release technology: a concise review sustained release drug disadvantagesInt J Res Dev Pharm Life Sci201322262269
   Google Scholar
• ParkKControlled drug delivery systems: past forward and future backJ Control Release20141903824794901
   PubMed Web of Science ®Google Scholar
• MüllertzAPerrieYRadesTAnalytical Techniques in the Pharmaceutical SciencesHeidelbergSpringer2016
   Google Scholar
• XuMLiewCVHengPWEvaluation of the coat quality of sustained release pellets by individual pellet dissolution methodologyInt J Pharm2015478131832725435182
   PubMedGoogle Scholar
• DavidsonRSKehoeGinventorsCure Pharmaceutical, assigneeMethods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and useUS patent8999372B2201547
   Google Scholar
• MccarthyCAAhernRJDontireddyRRyanKBCreanAMMes-oporous silica formulation strategies for drug dissolution enhancement: a reviewExpert Opin Drug Deliv20161319310826549623
   PubMed Web of Science ®Google Scholar
• KidaneABhattPPinventorsSupernus Pharmaceuticals, assigneeOsmotic drug delivery systemUS patent15162829201624
   Google Scholar
• ChenJPanHYeTRecent aspects of osmotic pump systems: functionalization, clinical use and advanced imaging technologyCurr Drug Metab201617327929126467064
   PubMed Web of Science ®Google Scholar
• ZamanMQureshiJEjazHOral controlled release drug delivery system and characterization of oral tablets: a reviewPak J Pharm Sci2016216776
   Google Scholar
• AuilerJFLiuKLynchJMGelotteCKEffect of Food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) studyCurr Med Res Opin200218531131612240794
   PubMed Web of Science ®Google Scholar
• ChaudhryNCSaundersLSustained release of drugs from ion exchange resinsJ Pharm Pharmacol195681197598613368094
   PubMed Web of Science ®Google Scholar
• SinghBNKimKHFloating drug delivery systems: an approach to oral controlled drug delivery via gastric retentionJ Control Release200063323525910601721
   PubMed Web of Science ®Google Scholar
• KumarVPrajapatiSSoniGCSinghMKumarNSustained release matrix type drug delivery system: a reviewWorld J Pharm Pharm Sci201213934960
   Google Scholar
• PundirSBadolaASharmaDSustained release matrix technology and recent advance in matrix drug delivery system: a reviewInt J Drug Res Technol2017311220
   Google Scholar
• NairLSLaurencinCTBiodegradable polymers as biomaterialsProg Polym Sci2007328–9762798
   Web of Science ®Google Scholar
• HaxhoFAllisonSAlghamdiFOseltamivir phosphate mono-therapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinomaBreast Cancer (Dove Med Press)2014619120325525387
   PubMedGoogle Scholar
• HaxhoFANeufeldRJSzewczukMRNovel insulin receptor-signaling platformInt J Diabetes Clin Res20141110
   Google Scholar
• GilmourAMAbdulkhalekSChengTSA novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancerCell Signal201325122587260323993964
   PubMed Web of Science ®Google Scholar
• AlghamdiFGuoMAbdulkhalekSCrawfordNAmithSRSzewczukMRA novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetesCell Signal20142661355136824583283
   PubMed Web of Science ®Google Scholar
• HaxhoFHaqSSzewczukMRBiased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signalingCell Signal201843718429277445
   PubMed Web of Science ®Google Scholar
• AbdulkhalekSAmithSRFranchukSLNeu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signalingJ Biol Chem201128642365323654921873432
   PubMed Web of Science ®Google Scholar
• HaxhoFNeufeldRJSzewczukMRNeuraminidase-1: a novel therapeutic target in multistage tumorigenesisOncotarget2016726408604088127029067
   PubMedGoogle Scholar
• HrynykMEllisJPHaxhoFTherapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinomaDrug Des Devel Ther2015945734586
   PubMed Web of Science ®Google Scholar
• O’SheaLKAbdulkhalekSAllisonSNeufeldRJSzewczukMRTherapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu) disables cancer cell survival in human pancreatic cancer with acquired chemoresistanceOnco Targets Ther2014711713424470763
   PubMed Web of Science ®Google Scholar
• KapishonVAllisonSWhitneyRACunninghamMFSzewczukMRNeufeldRJOseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platformBiomater Sci20164351152126788555
   PubMed Web of Science ®Google Scholar
• WoodKSzewczukMRRousseauDNeufeldRJOseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survivalOncotarget2018916127541276829560107
   PubMedGoogle Scholar
• WakaskarRRPromising effects of nanomedicine in cancer drug deliveryJ Drug Target201826431932428875739
   PubMed Web of Science ®Google Scholar
• ChoiKYYoonHYKimJHSmart nanocarrier based on PEGylated hyaluronic acid for cancer therapyACS Nano20115118591859921967065
   PubMed Web of Science ®Google Scholar
• SarkarKYangHEncapsulation and extended release of anticancer anastrozole by stealth nanoparticlesDrug Deliv200815534334618763165
   PubMed Web of Science ®Google Scholar
• TietjenGTSaltzmanWMNanomedicine gets personalSci Transl Med20157314314fs47
   PubMed Web of Science ®Google Scholar
• MaitlandMLSchilskyRLClinical trials in the era of personalized oncologyCA Cancer J Clin201161636538122034206
   PubMed Web of Science ®Google Scholar
• NicoliniCBragazziNPechkovaENanoproteomics enabling personalized nanomedicineAdv Drug Deliv Rev201264131522153122820526
   PubMed Web of Science ®Google Scholar
• KyddJJadiaRVelpurisivaPGadAPaliwalSRaiPTargeting strategies for the combination treatment of cancer using drug delivery systemsPharmaceutics201794E4629036899
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGDrug targeting to tumors: principles, pitfalls and (pre-)clinical progressJ Control Release2012161217518721945285
   PubMed Web of Science ®Google Scholar
• LiYWangYHuangGGaoJCooperativity principles in self-assembled nanomedicineChem Rev2018118115359539129693377
   PubMed Web of Science ®Google Scholar
• LuoMWangHWangZA STING-activating nanovaccine for cancer immunotherapyNat Nanotechnol201712764865428436963
   PubMed Web of Science ®Google Scholar